VIATRIS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
VIATRIS INC. (VTRS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $7.61 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.98, a 4.96% increase year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.65, a 26.27% decline year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.02, a 71.16% increase year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.27.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $6.83, a 2.57% decline from fiscal 2024.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $7.01, a 24.07% increase from fiscal 2023.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $5.65.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $21.13, a 46.74% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.61 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.98 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $6.83 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $6.59 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.51 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $6.65 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $7.01 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $6.99 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $7.02 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $9.02 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $5.65 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $5.77 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $5.67 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $5.27 10-Q · filed 2023-05-08 | |||
| 2020-12-31 | $21.13 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $14.40 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $21.75 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |